文献速递白血病淋巴瘤

维奈克拉治疗del(17p)慢性淋巴细胞白血病的2期试验6年随访及亚组分析

Six-year follow-up and subgroup analyses of a phase 2 trial of venetoclax for del(17p) chronic lymphocytic leukemia.
PubMed 文献 · Blood Adv · 2024-01-01

报告开放标签、多中心2期M13-982试验(NCT01889186)的6年随访分析:158例del(17p)慢性淋巴细胞白血病患者(初治5例、复发/难治153例)接受维奈克拉每日400 mg治疗后,最佳客观缓解率为77%(完全缓解21%、部分缓解49%),中位缓解持续时间39.3个月,中位无进展生存期28.2个月,中位总生存期62.5个月。

要点

  • 158例del(17p)慢性淋巴细胞白血病患者接受维奈克拉每日400 mg治疗,中位随访70个月。
  • 最佳客观缓解率77%(完全缓解21%、部分缓解49%),中位缓解持续时间39.3个月。
  • 中位无进展生存期28.2个月,中位总生存期62.5个月,6年后16%患者仍在治疗。

核心结论

  • 长期数据显示维奈克拉在del(17p)慢性淋巴细胞白血病患者中持续获益。

研究设计与样本

  • 开放标签、多中心2期M13-982试验(NCT01889186)的6年随访分析;共158例del(17p)慢性淋巴细胞白血病患者,其中初治5例、复发/难治153例。

主要发现

  • 中位随访70个月,最佳客观缓解率为77%(完全缓解21%、部分缓解49%),中位缓解持续时间39.3个月(95%CI 31.1-50.5)。
  • 中位无进展生存期28.2个月(95%CI 23.4-37.6),中位总生存期62.5个月(95%CI 51.7-未达到),6年后16%患者仍在治疗。
  • 多因素分析未发现由临床或实验室变量定义的患者亚组与客观缓解率或无进展生存期之间存在统计学显著相关性。
  • 最常见的≥3级不良事件为中性粒细胞减少(42%)、感染(33%)、贫血(16%)和血小板减少(16%)。
  • 事后比较分析在M13-982与MURANO研究之间,从治疗开始、从24个月界标及按微小残留病状态比较del(17p)患者的无进展生存期和总生存期。

关键数值与推荐

  • 维奈克拉每日400 mg,经初始剂量递增后给药,持续至疾病进展。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chromosome 17p deletion (del[17p]) is associated with poor prognosis in patients with chronic lymphocytic leukemia (CLL). Venetoclax is approved for treatment of previously untreated and relapsed/refractory (R/R) CLL, including patients with del(17p), based on the open-label, multicenter, phase 2 M13-982 trial (NCT01889186). Here, we detail the 6-year follow-up analysis for M13-982. A total of 158 patients with previously untreated (n = 5) or R/R (n = 153) del(17p) CLL received 400 mg venetoclax daily after initial ramp-up until progressive disease. After a median follow-up of 70 months, the best objective response rate (ORR) was 77% (21% complete remission [CR] and 49% partial remission [PR]), with a median duration of response (DOR) of 39.3 months (95% confidence interval [CI], 31.1-50.5). The median progression-free survival (PFS) was 28.2 months (95% CI, 23.4-37.6), and median overall survival (OS) was 62.5 months (95% CI, 51.7-not reached), with 16% of patients remaining on treatment after 6 years. Multivariable analysis did not identify statistically significant correlation between patient subgroups defined by clinical or laboratory variables and ORR or PFS. The most common grade ≥3 adverse events were neutropenia (42%), infections (33%), anemia (16%), and thrombocytopenia (16%). Post hoc comparative analyses of PFS and OS from treatment initiation, from a 24-month landmark, and by minimal residual disease status were performed between patients with del(17p) in the M13-982 and MURANO studies in the interest of understanding these data in another context. These long-term data show the continued benefits of venetoclax in patients with del(17p) CLL. The trial was registered at www.clinicaltrials.gov as #NCT01889186.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Stilgenbauer S, Tausch E, Roberts AW, et al. Six-year follow-up and subgroup analyses of a phase 2 trial of venetoclax for del(17p) chronic lymphocytic leukemia. Blood Adv. 2024. PMID: 38290108. doi:10.1182/bloodadvances.2023011741

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。